We are live on ! Find out more
ABCL icon

AbCellera Biologics
ABCL

183 hedge funds and large institutions have $980M invested in AbCellera Biologics in 2023 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 63 increasing their positions, 55 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

504% more call options, than puts

Call options by funds: $13.3M | Put options by funds: $2.2M

15% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 55

0.47% more ownership

Funds ownership: 44.73% → 45.19% (+0.47%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

10% less funds holding

Funds holding: 203 → 183 (-20)

24% less capital invested

Capital invested by funds: $1.3B → $980M (-$316M)

45% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 40

Holders
183
Holders Change
-20
Holders Change %
-9.85%
% of All Funds
2.92%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
22
Increased
63
Reduced
55
Closed
40
Calls
$13.3M
Puts
$2.2M
Net Calls
+$11.1M
Net Calls Change
-$189K

Top Buyers

1
Norges Bank
Norges Bank
Norway
+$8.44M
2
Millennium Management
Millennium Management
New York
+$7.08M
3
Renaissance Technologies
Renaissance Technologies
New York
+$6.26M
4
HF
HRT Financial
New York
+$5.05M
5
CS
Credit Suisse
Switzerland
+$4.61M

Top Sellers

1
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$8.89M
2
TC
TwinBeech Capital
New York
-$5.31M
3
N
Nuveen
North Carolina
-$3.58M
4
Man Group
Man Group
United Kingdom
-$3.09M
5
SFI
Susquehanna Fundamental Investments
Pennsylvania
-$2.06M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$6.86M +$2.49M +273,870 +43%
IP
27
Intellectus Partners
California
$6.58M +$35.4K +3,900 +0.4%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$5.94M -$64.5K -7,106 -0.9%
Two Sigma Investments
29
Two Sigma Investments
New York
$5.75M -$1.8M -198,366 -21%
PM
30
Prosight Management
Texas
$5.68M +$3.91M +430,774 +133%
JP Morgan Chase
31
JP Morgan Chase
New York
$5.36M +$1.07M +118,102 +20%
DFO
32
Duquesne Family Office
New York
$4.97M – – –
TWC
33
TD Waterhouse Canada
Ontario, Canada
$4.25M -$281K -30,931 -6%
N
34
Nuveen
North Carolina
$4.23M -$3.58M -393,836 -41%
HF
35
HRT Financial
New York
$4.19M +$5.05M +556,274 New
Two Sigma Advisers
36
Two Sigma Advisers
New York
$4.07M -$803K -88,400 -14%
Barclays
37
Barclays
United Kingdom
$3.92M +$1.85M +203,493 +64%
BC
38
Belmont Capital
California
$3.85M – – –
GCM
39
Graham Capital Management
Connecticut
$3.58M +$2.95M +325,051 +218%
Charles Schwab
40
Charles Schwab
California
$3.56M +$57.8K +6,362 +1%
FFGM
41
Founders Fund Growth Management
California
$3.07M – – –
Goldman Sachs
42
Goldman Sachs
New York
$2.65M -$1.03M -113,530 -24%
Deutsche Bank
43
Deutsche Bank
Germany
$2.29M +$770K +84,850 +39%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$2.27M +$58.1K +6,398 +2%
Ameriprise
45
Ameriprise
Minnesota
$2.2M +$434K +47,846 +20%
Aberdeen Group
46
Aberdeen Group
United Kingdom
$2.1M -$52.1K -5,735 -2%
ECM
47
ExodusPoint Capital Management
New York
$1.9M +$652K +71,842 +40%
COPPSERS
48
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$1.89M – – –
AllianceBernstein
49
AllianceBernstein
Tennessee
$1.76M – – –
MAM
50
Martingale Asset Management
Massachusetts
$1.37M +$547K +60,240 +49%
1
2
3 4 5

ABCL Hedge Fund Activity: Q1 2023 in Review

183 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q1 2023, worth a combined $980M — down 24% from $1.3B a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of ABCL and 22 opened new positions — a net loss of 18 holders — while 55 trimmed existing stakes and 63 added.

The largest buyer was Norges Bank, adding an estimated $8.44M. The largest seller was D.E. Shaw & Co, cutting an estimated $8.89M.

  • 183 institutional investors held AbCellera Biologics (ABCL) as of Q1 2023, down from 203 in Q4 2022.
  • Funds reported $980M of AbCellera Biologics stock for Q1 2023, down 24% quarter-over-quarter.
  • 22 funds opened new AbCellera Biologics positions in Q1 2023 and 40 closed out, a net change of -18 holders.
  • The largest AbCellera Biologics buyer in Q1 2023 was Norges Bank, an estimated $8.44M added.
  • The largest AbCellera Biologics seller in Q1 2023 was D.E. Shaw & Co, an estimated $8.89M sold.

Based on aggregated 13F filings for Q1 2023.